Author:
van der Putten Joost,van der Sommen Fons
Publisher
Springer International Publishing
Reference96 articles.
1. Arnold M, Soerjomataram I, Ferlay J, Forman D. Global incidence of oesophageal cancer by histological subtype in 2012. Gut. 2015;64(3):381–7.
2. Schölvinck DW, Van Der Meulen K, Bergman JJ, Weusten BL. Detection of lesions in dysplastic Barrett’s esophagus by community and expert endoscopists. Endoscopy. 2017;49(02):113–20.
3. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med. 2003;349(23):2241–52.
4. Cotton CC, Wolf WA, Overholt BF, Li N, Lightdale CJ, Wolfsen HC, Pasricha S, Wang KK, Shaheen NJ, Sampliner RE, et al. Late recurrence of Barrett’s esophagus after complete eradication of intestinal metaplasia is rare: final report from ablation in intestinal metaplasia containing dysplasia trial. Gastroenterology. 2017;153(3):681–8.
5. Phoa KN, Rosmolen WD, Weusten BL, Bisschops R, Schoon EJ, Das S, Ragunath K, Fullarton G, DiPietro M, Ravi N, et al. The cost-effectiveness of radiofrequency ablation for barrett’s esophagus with low-grade dysplasia: results from a randomized controlled trial (surf trial). Gastrointest Endosc. 2017;86(1):120–9.